Dong et al. found that DHX37 also serves as a crucial immune checkpoint (Dong et al., 2019), and knocking out DHX37 in CD8-positive T cells can enhance the effectiveness of adoptive immunotherapy against triple-negative breast cancer. The gene discussed is DHX37; the disease is triple-negative breast carcinoma.